Halozyme Therapeutics (HALO) Enterprise Value (2010 - 2026)
Halozyme Therapeutics (HALO) reported Enterprise Value of -$318.6 million for Q1 2026, up 57.4% year-over-year from -$202.4 million in Q1 2025, and down 123.09% quarter-over-quarter from -$142.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Enterprise Value (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Enterprise Value data on file, last reported at -$318.6 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$318.6 million, up 57.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$318.6 million (up 57.4% YoY), and the FY2025 annual result was -$142.8 million, up 76.04% from the prior year.
- Enterprise Value slipped to -$318.6 million in Q1 2026 per HALO's latest filing, from -$142.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$142.8 million in Q4 2025 and troughed at -$786.1 million in Q1 2022.
- A 5-year average of -$457.7 million and a median of -$463.5 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value tumbled 81.97% in 2023, then jumped 76.04% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$362.8 million in 2022, then advanced by 7.39% to -$336.0 million in 2023, then plunged by 77.4% to -$596.1 million in 2024, then jumped by 76.04% to -$142.8 million in 2025, then slumped by 123.09% to -$318.6 million in 2026.
- Business Quant data shows HALO's Enterprise Value at -$318.6 million in Q1 2026, -$142.8 million in Q4 2025, and -$702.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -584.73 Mn |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | -318.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -318.62 Mn |
| Dec 31, 2025 | -142.82 Mn |
| Sep 30, 2025 | -701.96 Mn |
| Jun 30, 2025 | -548.18 Mn |
| Mar 31, 2025 | -747.92 Mn |
| Dec 31, 2024 | -596.07 Mn |
| Sep 30, 2024 | -666.31 Mn |
| Jun 30, 2024 | -529.03 Mn |
| Mar 31, 2024 | -463.45 Mn |
| Dec 31, 2023 | -336.00 Mn |
| Sep 30, 2023 | -483.28 Mn |
| Jun 30, 2023 | -348.28 Mn |
| Mar 31, 2023 | -275.61 Mn |
| Dec 31, 2022 | -362.79 Mn |
| Sep 30, 2022 | -265.58 Mn |
| Jun 30, 2022 | -209.36 Mn |
| Mar 31, 2022 | -786.14 Mn |
| Dec 31, 2021 | -740.92 Mn |
| Sep 30, 2021 | -815.92 Mn |
| Jun 30, 2021 | -755.31 Mn |